N. Borgstein

发表

Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.

J. Djurhuus, R. Nijman, N. Borgstein, 2005, The Journal of urology.

Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women

Yijun Yang, Ravindra Kumar, N. Borgstein, 2013, Journal of clinical pharmacology.

A single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers

Ravi Kumar, Yijun Yang, J. Seehra, 2013, Muscle & nerve.

Blood Use in Adult Cardiac Surgery — Extrapolations from the Carola data base

A. F. Geus, N. Borgstein, H. Mungroop, 1991 .

ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis.

Yijun Yang, N. Borgstein, M. Sherman, 2009 .

Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity

N. Borgstein, P. Ellsworth, J. Djurhuus, 2005 .

P3.18 A Phase 1 multiple ascending dose study to assess the pharmacodynamic effects of ACE-031, an inhibitor of negative muscle regulators, in healthy volunteers

N. Borgstein, M. Sherman, K. Attie, 2010, Neuromuscular Disorders.

Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.

R. Nijman, N. Borgstein, P. Ellsworth, 2007, European urology.

Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity.

P. Reddy, R. Nijman, N. Borgstein, 2008, Journal of pediatric urology.

Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.

P. Reddy, R. Nijman, N. Borgstein, 2005, The Journal of urology.

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

F. Saad, N. Agarwal, D. Agus, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)

F. Saad, J. Nelson, H. Scher, 2014 .

Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial).

F. Saad, J. Bono, D. Agus, 2014, Clinical advances in hematology & oncology : H&O.

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

W. Chey, R. Boinpally, G. Sayuk, 2020, The American journal of gastroenterology.

AJG-20-1608 354..361

W. Chey, R. Boinpally, G. Sayuk, 2022 .

ACE-011, a Soluble Activin Receptor Type IIa IgG-Fc Fusion Protein, Increases Hemoglobin and Hematocrit Levels in Postmenopausal Healthy Women

Yijun Yang, N. Borgstein, M. Sherman, 2008 .

Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System

Lin Chang, B. Lacy, B. Moshiree, 2021, The American journal of gastroenterology.

M.P.1.03 Preliminary results from single subcutaneous administration of ACE-031, a form of the soluble activin type IIB receptor, in healthy postmenopausal volunteers

J. Lachey, J. Seehra, N. Borgstein, 2009, Neuromuscular Disorders.

Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

W. Oh, H. Pandha, K. Miller, 2015 .

AJG-20-3669 1929..1937

B. Lacy, B. Moshiree, R. Boinpally, 2022 .

CABG, aspirin, and transfusion.

N. Borgstein, S. Williams, R. G. Gallandat Huet, 1989, Journal of cardiothoracic anesthesia.

Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women

Yijun Yang, Ravindra Kumar, N. Borgstein, 2013, Journal of clinical pharmacology.

Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma.

H. Hurwitz, N. Solban, J. Bendell, 2010 .